Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the popular diabetes ... The injectable drugs have been in shortage since 2022.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

while the fourth will make injectable products, the Indianapolis-based drug giant said Wednesday. David Ricks, Eli Lilly’s chief executive officer, told CNN that the company – whose revenue grew 32% ...

Weight loss injectables like Ozempic have gained popularity in Bengaluru, with patients sourcing them from abroad. The ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound ... while the fourth will make injectable products, the Indianapolis-based drug giant said Wednesday.

Unlike Lilly’s injectable GLP-1 currently on ... of its GLP-1 semaglutide as Rybelsus, though the drug is only approved in type 2 diabetes. Meanwhile, Evercore ISI analyst Umer Raffat said ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity treatments continue to improve.